In a phase II, open-label, single-arm clinical trial, Bachelot et al. showed that the combination of sunitinib and trastuzumab had modest antitumor activity in HER2-positive advanced breast cancer, with greater benefit in less heavily pretreated patients; however, cardiac toxicity and other adverse events remain concerns, and the overall benefit did not appear superior to established dual HER2-targeted regimens [69]. This evidence concerns the gene ERBB2 and breast carcinoma.